Search Results - "Spertino, J."

Omalizumab for the treatment of chronic inducible urticaria in 80 patients by Exposito‐Serrano, V., Curto‐Barredo, L., Aguilera Peiro, P., Gómez Armayones, S., Serra‐Baldrich, E., Spertino, J., Bonfill Ortí, M., Figueras Nart, I., Melé‐Ninot, G., Baliu‐Piqué, C., Sala Cunill, A., Labrador‐Horrillo, M., Guilabert Vidal, A., Fernández Chico, N., Giménez‐Arnau, A.M.

Get full text

Long-term study of infliximab for psoriasis in daily practice: drug survival depends on combined treatment, obesity and infusion reactions by Spertino, J., López-Ferrer, A., Vilarrasa, E., Puig, L.

“…Background Infiximab has been shown to be highly effective in phase III clinical trials, but limited information is available regarding drug survival and…”
Get full text

Omalizumab updosing allows disease activity control in patients with refractory chronic spontaneous urticaria by Curto‐Barredo, L., Spertino, J., Figueras‐Nart, I., Expósito‐Serrano, V., Guilabert, A., Melé‐Ninot, G., Cubiró, X., Bonfill‐Ortí, M., Garcias‐Ladaria, J., Villar, M., García‐Navarro, X., Bielsa‐Marsol, I., Vilavella, M., Aparicio, G., Baliu‐Piqué, C., Álvarez, A., Lamas‐Domenech, N., Duran‐Jordà, X., Serra‐Baldrich, E., Giménez‐Arnau, A.

Get full text

Wells syndrome and chronic spontaneous urticaria: report of four cases successfully treated with omalizumab by Ogueta, I., Spertino, J., Deza, G., Alcantara Luna, S., Zaragoza Ninet, V., Pujol, R.M., Giménez‐Arnau, A.M.

Get full text

Definition of Recurrent Chronic Spontaneous Urticaria by Melé-Ninot, G, Serra-Baldrich, E, Curto-Barredo, L, Figueras-Nart, I, Spertino, J, Expósito-Serrano, V, García-Navarro, X, Guilabert, A, Bielsa-Marsol, I, Giménez-Arnau, A

“…Abstract is missing (Short communication)…”
Get full text

The Effectiveness of Omalizumab Treatment in Real-Life is Lower in Patients with Chronic Urticaria Longer than 18 Months’ Evolution and Prior Immunosuppressive Treatment by Cubiró, X., Spertino, J., Rozas-Muñoz, E., Serra-Baldrich, E., Puig, L.

“…The efficacy of omalizumab in the treatment of chronic spontaneous urticaria has been demonstrated in phase iii clinical trials, but limited information is…”
Get full text

The Effectiveness of Omalizumab Treatment in Real-Life is Lower in Patients with Chronic Urticaria Longer than 18 Months' Evolution and Prior Immunosuppressive Treatment by Cubiró, X, Spertino, J, Rozas-Muñoz, E, Serra-Baldrich, E, Puig, L

“…BACKGROUNDThe efficacy of omalizumab in the treatment of chronic spontaneous urticaria has been demonstrated in phase iii clinical trials, but limited…”
Get full text

Algorithm for Treatment of Chronic Spontaneous Urticaria with Omalizumab by Spertino, J, Curto Barredo, L, Rozas Muñoz, E, Figueras Nart, I, Gimenez Arnau, A, Serra Baldrich, E, Bonfill-Ortí, M, Expósito-Serrano, V, Guilabert, A, Melé Ninot, G, Villar Buil, M, Garcias Ladaria, J, García Navarro, X, Vilavella, M, Bielsa Marsol, I, Aparicio Ortiz, G, Baliu Piqué, C, Álvarez Abella, A, Lamas Domenech, N, Mascaró, J M, Gómez, S, Torné Gutiérrez, J I, Vicente Villa, A

“…BACKGROUND AND OBJECTIVEPivotal trials with omalizumab for treatment of chronic spontaneous urticaria (CSU) are generally run over 12 to 24weeks. However, in…”
Get full text

Algorithm for Treatment of Chronic Spontaneous Urticaria with Omalizumab by Spertino, J., Curto Barredo, L., Rozas Muñoz, E., Figueras Nart, I., Serra Baldrich, E., Bonfill-Ortí, M., Expósito-Serrano, V., Guilabert, A., Melé Ninot, G., Villar Buil, M., Garcias Ladaria, J., García Navarro, X., Vilavella, M., Bielsa Marsol, I., Aparicio Ortiz, G., Baliu Piqué, C., Álvarez Abella, A., Lamas Domenech, N., Mascaró, J.M., Gómez, S., Torné Gutiérrez, J.I., Vicente Villa, A., Gimenez Arnau, A.

“…Pivotal trials with omalizumab for treatment of chronic spontaneous urticaria (CSU) are generally run over 12 to 24weeks. However, in clinical practice, many…”
Get full text

5PSQ-113 Real-life effectiveness, safety and adherence of dupilumab in patients with atopic dermatitis by Socias Cañellas, C, Riera, P, Masip, M, Serra-Baldrich, E, Spertino, J, Roé-Crespo, E, Pagès-Puigdemont, N

“…Background and ImportanceDupilumab, an anti-IL-4/13, is a monoclonal antibody approved for the treatment of moderate-to-severe atopic dermatitis (AD). So far,…”
Get full text